Publications and Research

• King, J. C., Jr., Stoddard, J. J., Gaglani, M. J., Moore, K. A., Magder, L., McClure, E., Rubin, J. D., Englund, J. A., and Neuzil, K.
  Effectiveness of school-based influenza vaccination. N.Engl.J Med 355[24], 2523-2532. 12-14-2006.
• Piedra, P. A., Gaglani, M. J., Riggs, M., Herschler, G., Fewlass, C., Watts, M., Kozinetz, C., Hessel, C., and Glezen, W. P.
  Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116[3], e397-e407. 2005.
• Piedra, P. A., Gaglani, M. J., Kozinetz, C. A., Herschler, G., Riggs, M., Griffith, M., Fewlass, C., Watts, M., Hessel, C., Cordova, J., and Glezen, W. P.
  Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23[13], 1540-1548. 2-18-2005.
• Gaglani, M. J., Piedra, P. A., Herschler, G. B., Griffith, M. E., Kozinetz, C. A., Riggs, M. W., Fewlass, C., Halloran, M. E., Longini, I. M., Jr., and Glezen, W. P.
  Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Archives of Pediatrics and Adolescent Medicine 158[1], 65-73. 2004.
• Read more publications.